Maravai LifeSciences Financial Ratios
NASDAQ: MRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Maravai LifeSciences ratio analysis
Maravai LifeSciences earned a net margin of -70.4% in FY 2025, down from -55.9% a year earlier. Gross margin was 18.3% compared with a median of 62.6% over the prior 6 years. Return on equity reached -61.6%, meaning Maravai LifeSciences generated -0.62 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 1.37 versus 0.91 the year before, and the current ratio was 6.60. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Maravai LifeSciences financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | 8.57 | 26.86 | 11.89 | — |
| Price / sales | 2.64 | 3.02 | 2.99 | 2.13 | 6.02 | 1.02 | — |
| Price / book | 2.31 | 2.41 | 2.07 | 3.45 | 15.24 | 3.28 | — |
| Gross margin | 18.3% | 41.8% | 48.5% | 80.9% | 82.4% | 72.0% | 53.3% |
| Operating margin | -115.9% | -90.9% | -11.0% | 65.0% | 69.4% | 42.2% | 16.8% |
| Net margin | -70.4% | -55.9% | -41.2% | 24.9% | 22.8% | 31.3% | -3.1% |
| Free cash flow margin | -38.1% | -8.6% | 21.0% | 58.8% | 44.3% | 44.6% | 4.9% |
| Return on equity (ROE) | -61.6% | -44.5% | -28.6% | 40.4% | 57.7% | 100.5% | -3.1% |
| Return on assets (ROA) | -17.0% | -14.4% | -8.0% | 9.6% | 9.5% | 7.0% | — |
| Debt / equity | 1.37 | 0.91 | 1.26 | 0.97 | 1.68 | 6.04 | — |
| Current ratio | 6.60 | 7.53 | 8.00 | 7.70 | 7.89 | 2.54 | — |
| Revenue growth | -28.3% | -10.3% | -67.3% | 10.5% | 181.3% | 98.5% | — |
| EPS growth | — | — | -153.9% | 7.1% | -33.9% | — | — |